You are here

Modular antibody engineering to overcome the blood brain barrier

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43NS105172-01
Agency Tracking Number: R43NS105172
Amount: $236,646.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: 105
Solicitation Number: PA16-302
Solicitation Year: 2016
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-09-25
Award End Date (Contract End Date): 2019-08-31
Small Business Information
Pottstown, PA 19464-3468
United States
DUNS: 962964990
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (610) 990-7531
Business Contact
Phone: (610) 990-7531
Research Institution

Abstract Immunotherapy is one of the most promising approaches for treatment of various human diseases
including cancers autoimmune and infectious diseases However systemic immunotherapies have been ineffective
for central nervous system CNS disorders because the blood brain barrier BBB limits their delivery to the brain
Development of new antibody agents able to overcome the BBB is a new frontier of immunotherapy One strategy
is to use receptor mediated transport to deliver biologics across the BBB Abzyme proposes to use its proprietary
SDALib platform for rapid generation of antibodies to receptors present in the CNS and its Abz technology for
reformatting traditional antibodies to create bispecific antibodies that can overcome the BBB via receptor mediated
transcytosis and binding its specific target in the brain
Using Abzymeandapos s SDALib platform camelid single domain antibodies against human transferrin receptor TfR have
already been developed and generation of VHH antibodies to leptin receptor LepR is in progress In addition a set
of murine monoclonal antibodies against human protein targets of diagnostic and therapeutic significance is in
our possession The focus of Phase I is to demonstrate the feasibility of rapidly transforming disease specific
traditional antibodies into IgG like bispecific antibodies preserving antibody Fc effector functions and antibody
binding affinity and the ability of the newly obtained bispecifics to cross the BBB Specifically bispecific
recombinant antibodies with one arm targeting HER or EGFR and another arm against TfR or LepR will be
developed Demonstration of the robustness of bispecific antibody production and BBB penetration in cell based
BBB models and small animals will be the basis for Phase II application submission
Phase II work focus includes i obtaining the preclinical in vivo therapeutic efficacy pharmacodynamics
pharmacokinetics and toxicity data for antibodies developed in Phase I that are necessary for submission of an IND
ii using the SDALib antibody generation platform and Abz bispecific approach to produce of a suite of BBB
penetrating antibodies relevant to CNS disorders
Narrative Immunotherapy targeting cell surface and extracellular proteins is one of the most promising approaches
for treatment of various human diseases but has yet to be applied to central nervous system disorders due to the
blood brain barrier As a result of this project a suite of novel IgG like bispecific antibodies capable of overcoming
the BBB will be produced for treatment of various CNS disorders

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government